文献速递血液净化与透析慢性肾脏病

罗沙司他治疗初始透析的终末期肾病患者贫血

Roxadustat for anemia in patients with end-stage renal disease incident to dialysis.
PubMed 文献 · Nephrol Dial Transplant · 2021-01-01

HIMALAYAS 是一项 3 期开放标签、促红素α对照试验,纳入初始透析 2 周至 ≤4 个月的成人患者(平均 Hb ≤10.0 g/dL)。罗沙司他在 28–52 周平均 Hb 变化及 1–24 周 Hb 应答率上均非劣于促红素α,不良事件率两组相当。

要点

  • 罗沙司他在初始透析患者中纠正和维持 Hb 非劣于促红素α。
  • 28–52 周平均 Hb 变化:罗沙司他 2.57 g/dL,促红素α 2.36 g/dL。
  • 两组不良事件发生率相当。

核心结论

  • 罗沙司他可有效纠正和维持初始透析的终末期肾病患者的 Hb 水平,疗效非劣于促红素α。
  • 罗沙司他安全性可接受,不良事件率与促红素α相当。

研究设计与样本

  • HIMALAYAS 为 3 期、开放标签、促红素α对照试验。
  • 纳入随机化前 2 周至 ≤4 个月初始血液透析/腹膜透析、平均 Hb ≤10.0 g/dL 的成人患者。
  • 意向治疗人群:罗沙司他组 n=522,促红素α组 n=521。

主要发现

  • 28–52 周平均 Hb 较基线变化:罗沙司他组 2.57(1.27)g/dL,促红素α组 2.36(1.21)g/dL。
  • 罗沙司他非劣于促红素α:最小二乘均值差 0.18(95%CI 0.08,0.29)。
  • 1–24 周 Hb 应答率:罗沙司他组 88.2%,促红素α组 84.4%。
  • Hb 应答率组间差异 3.5%(95%CI -0.7%,7.7%),罗沙司他非劣于促红素α。
  • 两组不良事件率相当。

关键数值与推荐

  • 主要终点 1:28–52 周平均 Hb 较基线变化,非劣性标准为治疗差异 95%CI 下限 >-0.75。
  • 主要终点 2:1–24 周 Hb 应答率(对救援治疗删失),非劣性界值为组间差异 -15%。

临床怎么用

  • 对于初始透析的终末期肾病贫血患者,罗沙司他可作为促红素α的替代选择。
  • 需监测 Hb 水平及不良事件,疗效与安全性特征与促红素α相当。

局限性

  • 为开放标签设计。
  • 仅纳入初始透析 2 周至 ≤4 个月的患者,结论外推需谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: We evaluated the efficacy and safety of roxadustat versus epoetin alfa for the treatment of chronic kidney disease-related anemia in patients new to dialysis. METHODS: HIMALAYAS was a Phase 3, open-label, epoetin alfa-controlled trial. Eligible adults were incident to hemodialysis/peritoneal dialysis for 2 weeks to ≤4 months prior to randomization and had mean hemoglobin (Hb) ≤10.0 g/dL. Primary endpoints were mean Hb (g/dL) change from baseline averaged over Weeks 28-52 regardless of rescue therapy [non-inferiority criterion: lower limit of 95% confidence interval (CI) for treatment difference >-0.75] and percentage of patients achieving an Hb response between Weeks 1 and 24 censored for rescue therapy (non-inferiority margin for between-group difference -15%). Adverse events were monitored. RESULTS: The intent-to-treat population included patients randomized to roxadustat (n = 522) or epoetin alfa (n = 521). Mean (standard deviation) Hb changes from baseline averaged over Weeks 28-52 were 2.57 (1.27) and 2.36 (1.21) in the roxadustat and epoetin alfa groups. Roxadustat was non-inferior [least squares mean difference: 0.18 (95% CI 0.08, 0.29)] to epoetin alfa. Percentages of patients with an Hb response were 88.2% and 84.4% in the roxadustat and epoetin alfa groups, respectively. Roxadustat was non-inferior to epoetin alfa [treatment-group difference 3.5% (95% CI -0.7%, 7.7%)]. Adverse event rates were comparable between treatment groups. CONCLUSIONS: Roxadustat was efficacious for correcting and maintaining Hb levels compared with epoetin alfa. Roxadustat had an acceptable safety profile.

来源:Nephrol Dial Transplant,查看原文。版权归原作者所有。

引用

  1. Provenzano R, Shutov E, Eremeeva L, et al. Roxadustat for anemia in patients with end-stage renal disease incident to dialysis. Nephrol Dial Transplant. 2021. PMID: 33629100. doi:10.1093/ndt/gfab051

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。